In a Nod to Precision Oncology, the FDA Approves Revumenib
The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.
Read More
Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.
Read More